SCHEMBL935213

SCHEMBL935213

CC(OC(=O)CCC(=O)O)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 2/20 0.45
KDM2A Q9Y2K7 2/20 0.45
KDM6B O15054 1/20 0.45
KDM5C P41229 1/20 0.45
PHF8 Q9UPP1 1/20 0.45
CYP1A2 P05177 1/20 0.43
LMNA P02545 4/20 0.41
ALKBH5 Q6P6C2 1/20 0.41
SUCNR1 Q9BXA5 1/20 0.41
SLC15A2 Q16348 1/20 0.39
GABRP O00591 2/20 0.38
GABRD O14764 2/20 0.38
GABRA1 P14867 2/20 0.38
GABRB1 P18505 2/20 0.38
GABRG2 P18507 2/20 0.38
GABRB3 P28472 2/20 0.38
GABRA5 P31644 2/20 0.38
GABRA3 P34903 2/20 0.38
GABRA2 P47869 2/20 0.38
GABRB2 P47870 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylene Glycol SCHEMBL2424946 0.94 EGLN1 (0.41) EGLN1KDM2AKDM6BKDM5CPHF8
SCHEMBL2608669 0.93 LMNA (0.40) EGLN1KDM2AKDM6BKDM5CPHF8
SCHEMBL7110445 0.93 LMNA (0.40) EGLN1KDM2AKDM6BKDM5CPHF8
SCHEMBL20511568 0.92 EGLN1 (0.39) EGLN1KDM2AKDM6BKDM5CPHF8
1,4-Butanediol SCHEMBL2420738 0.90 GPR84 (0.43) EGLN1KDM2AKDM6BKDM5CPHF8
Acetic Acid SCHEMBL22769870 0.88 LMNA (0.38) CYP1A2LMNATSHRMMP1MMP2
SCHEMBL9817250 0.86 LMNA (0.50) CYP1A2LMNATSHRMMP1MMP2
SCHEMBL18218913 0.84 ALDH1A1 (0.43) CYP1A2LMNASLC15A2TSHRMMP1
SCHEMBL19107033 0.83 LMNA (0.34) CYP1A2LMNATSHRMMP1MMP2
Ethylene Glycol SCHEMBL2422842 0.82 TSHR (0.44) LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117844878-A Method for producing polyglutamic acid by fermenting glutamic acid extracting solution 内蒙古阜丰生物科技有限公司 2024-04-09 CN disclosed
EP-4299705-A1 A PROCESS FOR MAKING A COMPOSITION COMPRISING ALKYL POLYGLYCOSIDE AND PERFUME The Procter & Gamble Company (US) 2024-01-03 EP disclosed
US-20230414474-A1 PROCESS FOR MAKING A COMPOSITION COMPRISING ALKYL POLYGLYCOSIDE AND PERFUME THE PROCTER & GAMBLE COMPANY 2023-12-28 US disclosed
CN-218842095-U Fermenting installation is used in grape wine making 紫云自治县格凸红生态食品开发有限公司 2023-04-11 CN disclosed
EP-4104857-A1 ANTI-CD137 ANTIGEN-BINDING MOLECULE FOR USE IN CANCER TREATMENT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-12-21 EP disclosed
US-10696930-B2 Solvent containing anitmicrobial hard surface cleaning compositions THE PROCTER & GAMBLE COMPANY (US) 2020-06-30 US disclosed
US-10647948-B2 Polymer containing antimicrobial hard surface cleaning compositions THE PROCTER & GAMBLE COMPANY (US) 2020-05-12 US disclosed
CN-210085412-U Household type wine brewing device 淮南师范学院 2020-02-18 CN disclosed
US-20180371369-A1 FABRIC TREATMENT THE PROCTER & GAMBLE COMPANY 2018-12-27 US disclosed
WO-2018237129-A1 SOLVENT CONTAINING HARD SURFACE CLEANING COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 2018-12-27 WO disclosed
WO-2009073557-A2 BIOLOGICAL SYSTEMS FOR PRODUCTION OF COMMERCIALLY VALUABLE COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-06-11 WO disclosed
WO-2008107390-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING A CALCILYTIC AGENT NOVARTIS AG (CH) 2008-09-12 WO disclosed
EP-1964548-A1 Pharmaceutical compositions comprising a calcilytic agent Novartis AG (CH) 2008-09-03 EP disclosed
WO-2008077591-A2 PHARMACEUTICAL FORMULATION COMPRISING NEUROKININ ANTAGONIST NOVARTIS AG (CH) 2008-07-03 WO disclosed
EP-1938804-A1 Pharmaceutical formulation comprising neurokinin antagonist Novartis AG (CH) 2008-07-02 EP disclosed
US-6441206-B1 HYDROXY ACID, DICARBOXYLIC ACID OR AMINO ACID ESTERS OF A PHYTOSTEROL AND/OR PHYTOSTANOL, PREFERABLY BETA SITOSTEROL AND SITOSTANOL; INHIBIT ABSORPTION OF CHOLESTEROL; INCREASE INTERACTION BETWEEN HYDROPHOBIC LIPID PHASE AND WATER PHASE RAISIO BENECOL LTD. (FI) 2002-08-27 US disclosed
EP-1015476-A1 USE OF ORGANIC ACID ESTERS IN DIETARY FAT Raisio Benecol Ltd. (FI) 2000-07-05 EP disclosed
US-5965743-A AS ANTIHYPERLIPEMIC AGENT; THERAPEUTIC AND PREVENTIVE DRUGS FOR ARTERIOSCLEROSIS NIPPON SODA CO., LTD. (JP) 1999-10-12 US disclosed
WO-1999015546-A1 USE OF ORGANIC ACID ESTERS IN DIETARY FAT RAISIO BENECOL LTD. (FI) 1999-04-01 WO disclosed
US-4110438-A METHOD OF TREATING DEPRESSION AMERICAN HOME PRODUCTS CORPORATION (US) 1978-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647948-B2 Polymer containing antimicrobial hard surface cleaning compositions CUTA, SIGLEC7, SDC1 EGLN1 2846/4885KDM2A 1021/4885KDM6B 2127/4885
US-10696930-B2 Solvent containing anitmicrobial hard surface cleaning compositions CUTA, SHARPIN, ITGAM EGLN1 4107/4885KDM2A 1696/4885KDM6B 2241/4885
US-20230414474-A1 PROCESS FOR MAKING A COMPOSITION COMPRISING ALKYL POLYGLYCOSIDE AND PERFUME FUT8, PLG, PIGS EGLN1 1077/4885KDM2A 3841/4885KDM6B 3172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.